IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BAKER BROS. ADVISORS LP | Director | Mar 28 '24 | Buy | 9.62 | 97,473 | 937,632 | 3,753,480 | Mar 28 07:04 PM | BAKER BROS. ADVISORS LP | Director | Mar 27 '24 | Buy | 9.24 | 27,844 | 257,170 | 3,664,073 | Mar 28 07:04 PM | BAKER BROS. ADVISORS LP | Director | Mar 26 '24 | Buy | 8.26 | 270,000 | 2,230,767 | 3,638,533 | Mar 28 07:04 PM | Schwarzer Fred | CEO AND PRESIDENT | Mar 14 '24 | Sale | 10.17 | 4,182 | 42,533 | 216,651 | Mar 15 07:51 PM | Tahir Misbah | CHIEF FINANCIAL OFFICER | Mar 14 '24 | Sale | 10.17 | 2,543 | 25,864 | 90,418 | Mar 15 07:53 PM | Takimoto Chris H | CHIEF MEDICAL OFFICER | Mar 14 '24 | Sale | 10.17 | 2,535 | 25,782 | 94,388 | Mar 15 07:55 PM | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Mar 14 '24 | Sale | 10.17 | 1,844 | 18,754 | 171,856 | Mar 15 07:49 PM | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Mar 14 '24 | Sale | 10.17 | 1,578 | 16,049 | 61,006 | Mar 15 07:48 PM | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Mar 14 '24 | Sale | 10.17 | 464 | 4,719 | 26,507 | Mar 15 07:57 PM | Schwarzer Fred | CEO AND PRESIDENT | Mar 13 '24 | Sale | 9.88 | 4,765 | 47,055 | 220,833 | Mar 15 07:51 PM | Tahir Misbah | CHIEF FINANCIAL OFFICER | Mar 13 '24 | Sale | 9.88 | 2,897 | 28,608 | 92,961 | Mar 15 07:53 PM | Takimoto Chris H | CHIEF MEDICAL OFFICER | Mar 13 '24 | Sale | 9.88 | 2,889 | 28,529 | 96,923 | Mar 15 07:55 PM | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Mar 13 '24 | Sale | 9.88 | 2,101 | 20,748 | 173,700 | Mar 15 07:49 PM | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Mar 13 '24 | Sale | 9.88 | 1,798 | 17,756 | 62,584 | Mar 15 07:48 PM | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Mar 13 '24 | Sale | 9.88 | 529 | 5,224 | 26,971 | Mar 15 07:57 PM | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Mar 01 '24 | Option Exercise | 0.93 | 3,026 | 2,814 | 4,039 | Mar 05 07:34 PM | BAKER BROS. ADVISORS LP | Director | Dec 15 '23 | Buy | 6.55 | 288,007 | 1,887,531 | 3,390,323 | Dec 15 05:32 PM | BAKER BROS. ADVISORS LP | Director | Dec 14 '23 | Buy | 6.50 | 157,370 | 1,023,157 | 3,123,585 | Dec 15 05:32 PM | BAKER BROS. ADVISORS LP | Director | Dec 13 '23 | Buy | 5.96 | 87,316 | 520,776 | 2,977,836 | Dec 15 05:32 PM | Schwarzer Fred | CEO and President | Dec 13 '23 | Sale | 5.78 | 17,576 | 101,558 | 102,848 | Dec 15 07:20 PM | Keyt Bruce | Chief Scientific Officer | Dec 13 '23 | Sale | 5.78 | 7,574 | 43,764 | 129,551 | Dec 15 07:19 PM | Decker Lisa Lynn | Chief Business Officer | Dec 13 '23 | Sale | 5.78 | 4,369 | 25,245 | 35,632 | Dec 15 07:18 PM | Takimoto Chris H | Chief Medical Officer | Nov 29 '23 | Sale | 6.21 | 1,180 | 7,331 | 53,562 | Dec 01 07:03 PM | Decker Lisa Lynn | Chief Business Officer | Nov 29 '23 | Sale | 6.21 | 1,180 | 7,331 | 40,001 | Dec 01 07:01 PM | Gauthier George | Chief Commercial Officer | Nov 29 '23 | Sale | 6.21 | 1,180 | 7,331 | 39,642 | Dec 01 07:02 PM | Tahir Misbah | Chief Financial Officer | Nov 27 '23 | Sale | 5.06 | 1,337 | 6,764 | 49,608 | Nov 29 08:49 PM | Schwarzer Fred | CEO and President | Nov 27 '23 | Sale | 5.06 | 1,337 | 6,764 | 120,424 | Nov 29 08:48 PM | Keyt Bruce | Chief Scientific Officer | Nov 27 '23 | Sale | 5.06 | 933 | 4,720 | 137,125 | Nov 29 08:47 PM | Gauthier George | Chief Commercial Officer | Oct 02 '23 | Sale | 7.95 | 935 | 7,430 | 39,082 | Oct 03 07:55 PM | Gauthier George | Chief Commercial Officer | Jul 03 '23 | Sale | 9.42 | 936 | 8,818 | 40,017 | Jul 05 09:08 PM | Topsoe Jakob Haldor | Director | Jun 30 '23 | Buy | 9.25 | 3,500 | 32,375 | 81,644 | Jul 03 06:46 PM | Topsoe Christina Teng | Director | Jun 30 '23 | Buy | 9.32 | 3,000 | 27,957 | 9,800 | Jul 05 09:07 PM | Redmile Group, LLC | Director | Jun 29 '23 | Buy | 9.42 | 80,423 | 757,585 | 2,974,186 | Jul 03 09:45 PM | Topsoe Jakob Haldor | Director | Jun 29 '23 | Buy | 9.10 | 3,500 | 31,846 | 78,144 | Jul 03 06:46 PM | Redmile Group, LLC | Director | Jun 29 '23 | Sale | 9.42 | 80,423 | 757,585 | 2,893,763 | Jul 03 09:45 PM | BEHRENS M KATHLEEN | Director | Jun 26 '23 | Buy | 8.00 | 112,500 | 900,000 | 330,700 | Jun 28 07:34 PM |
|